Biomanufacturing capacity optionality
Sponsored by: Cytiva
- Biomanufacturing Manufacturing Solutions
Date: 15 December
Days to go: 15
Time: 4PM London / 8AM California
Considerations when evaluating biomanufacturing expansion planning
A recent BioPlan survey, reported that more than 50 percent of biomanufacturers expect to experience moderate to serve commercial scale capacity constraints by 2025. With thousands of clinical trials underway, and growing pressures to support new vaccines and therapeutics for SARS COVID -19, the gap in manufacturing capacity will certainly increase rapidly. Critical assessments are needed for the various manufacturing options that can offer flexibility, speed and confidence needed to respond to critical shortages.
Long wait times and potential loss of intellectual property at contract manufacturing sites have led many biomanufacturers to explore their own manufacturing facility and platform prospects. The various options for addressing biomanufacturing capacity span from greenfield construction of an entire campus to retrofitting and existing site to modular solutions. The best fit must be imperially determined from analysis of the unique business strategy. Opportunities to include standard design and manufacturing platforms can offer distinct advantages and de-risk investments.
Five subject matter experts who have extensive experience designing and installing a wide assortment of biomanufacturing solutions across the globe will discuss the pros and cons of the different biomanufacturing facilities and platform choices that exist. Join for a pragmatic assessment of your options to efficiently build or retrofit to meet your business needs now and into the future.
Joe Makowiecki ,
Director of Business Development Enterprise Solutions, Cytiva
Joe has been in the Bioprocess industry for 25 years and has held management, senior management and director positions within Process Development, Pilot Plant, cGMP Manufacturing and Enterprise Solutions organizations. As Cytiva’s Director of Business Development for Enterprise Solutions, his responsibilities include product management of the FlexFactory (single-use, flexible and deployable biomanufacturing platforms), strategy for both the FlexFactory and KUBio (modular facility solutions) offerings, new technology identification and integration and commercial activation.
Joe’s expertise and experience includes downstream process development, scale up, cGMP manufacturing, process technical transfer, manufacturing site operations, contract manufacturing services, bioprocess solution selling and business development. He has been involved with the development, technical transfer, scale-up and manufacture of multiple diagnostic, vaccine and bio therapeutic products from mammalian, microbial and insect expression systems.
Program Director, Enterprise Solutions, Cytiva
Steve has 34 years of experience in the design, construction, commissioning, qualification and operation of biologics, pharmaceutical, and chemical facilities in the US, Europe, and Asia. He has supported over $1billion in capital projects since 2001 in the life sciences industry and has managed a portfolio of $300million in capital investments from project establishment through regulatory licensure.
As Program Director at Cytiva he is responsible for the development, design, and execution of the KUBioTM box modular biomanufacturing program for different modalities such as mAbs, viral vectors, plasmids, etc. He was also the founding technical creator of the BioPark biomanufacturing campus Program and has also managed strategic relationships with engineering and modular partners. Steve has an extensive process and project engineering background which augments his expertise in the development of GMP facilities through product licensure.
VP Quality and Regulatory, Germfree
Carol Houts is the Vice President of Quality and Regulatory for Germfree, an offsite clean room construction company that provides facility solutions for biopharmaceutical applications. Carol is an executive with over 25 years’ experience in pharmaceutical, and biologics product development, quality, regulatory affairs and clinical research. Carol has worked intensively to have constructive and cooperative interactions with the FDA and other global regulatory agencies through formal meetings, regulatory submissions, inspections and compliance remediation projects. Prior to joining Germfree Carol has worked extensively to build companies organizational and service capabilities to increase revenue and sustain long-term growth. Carol has led business development activities to achieve funding, and developed business plans for demonstrating investment opportunities.
Noel Maestre is a Biotech Core Team leader at CRB, with an emphasis on Advanced Therapy Medicinal Products (ATMPs). Noel comes from an extensive background in mechanical and process utilities engineering with experience in the life science industry.). Noel specializes in the design, construction and startup of biotechnology, pharmaceutical and advanced technology facilities, and has emerged as a cell and gene therapy Subject Matter Expert. Maestre is experienced in traditional biotechnology/pharmaceutical facility design, including a concentration on single-use process systems, batch versus continuous process and emerging technologies, such as cell and gene therapy. His focus as a project manager is to provide the right solution for the specific problem—true turnkey delivery, lean concepts and innovative project execution are key goals when delivering projects. Maestre is a graduate of Pennsylvania State University with a Bachelor of Science in mechanical engineering.
Peter Walters is a process engineer with 15 years of experience. He specializes in pharmaceutical process and facility design. He is an industry-recognized subject matter expert in the advanced therapy medicinal product field and frequently speaks at industry conferences and events. He has a strong technical background designing equipment and processes for multi-process facilities predicated on maximum flexibility, logistics optimization and technologies that reduce overhead costs, allow for pipeline expandability and produce a higher quality therapeutic. Coupled with his approachable business acumen, he is well respected for guiding clients to understand the impacts of facility design choices and acts as a steward to clients, assisting with the best decisions for their business and bottom line. Peter graduated from the University of California, Davis with a degree in chemical/biochemical engineering.
Key Learning Objectives
- Understand your options for building from greenfield, retrofitting an existing facility or utilizing modular biomanufacturing environments
- Increase awareness of the benefits of a standard design in biomanufacturing
- Explore modular facility options at different biomanufacturing scales
- Gain an appreciation for a configurable single-use manufacturing platforms for biomanufacturing
- Decision makers looking for in Biomanufacturing capacity efficiencies with job titles that include:
- Vice President
- Senior Vice president
- manufacturing engineer